by PEPID Newsroom | Jul 16, 2019 | Press & Media
– PEPID, the world’s leading provider of specialty medical and nursing software, and Data Soft Logic Corporation, creator of web-based point-of-care software optimized for home health, hospice, and therapy agencies, announced a ten-year renewal of their long-standing partnership. PEPID and Data Soft Logic first started working together in 2011.
by PEPID Newsroom | Jul 11, 2019 | Alerts
New study shows C-reactive protein (CRP) testing in primary care clinics for patients with Chronic Obstructive Pulmonary Disease (COPD) reduces patient-reported antibiotic use or receiving antibiotic prescriptions for exacerbation of COPD with no evidence of harm....
by PEPID Newsroom | Jul 10, 2019 | Alerts
According to the NutriNet-Sante prospective cohort study of 101,257 participants with the mean age of 42 and a medium follow-up of 5 years, sugary drinks like soda and fruit juices show a significant association of risk of overall cancer, and breast cancer....
by PEPID Newsroom | Jul 9, 2019 | Alerts
According to a report published in the Annals of Internal Medicine by the American College of Physicians, there is no benefit from antibiotic treatment exceeding the shortest effective duration when treating hospitalized patients with pneumonia. Excess days were...
by PEPID Newsroom | Jul 8, 2019 | Alerts
In a report published July 8, 2019 in JAMA Network, dispensing oral contraceptive pills 12-months rather than 3-months saves money and provides better support for women’s reproductive goals and autonomy. The study was done to estimate the financial and reproductive...
by PEPID Newsroom | Jul 2, 2019 | Alerts
A recent study published in the American Academy of Neurology observed a significant association between low-density lipoprotein cholesterol (LDL-C) concentrations and intracerebral hemorrhage (ICH) risk. The current cohort study included 96,043 participants with the...
by Anna Tan | Jun 24, 2019 | Emergency Medicine, Nursing, Pharmacy, Primary Care
Summer is in full swing, and what better way to welcome the hottest time of the year than with a fun-filled weekend in the great outdoors. Whether you’re unwinding in a private cabin in the woods or pitching a cozy tent by the lake, too much exposure and too...
by PEPID Newsroom | Jun 21, 2019 | Alerts
FDA approves bremelanotide (Vyleesi, AMAG Pharmaceuticals) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Bremelanotide is the first-in-class melanocortin 4 receptor agonist for HSDD, and joins Flibanserin as...
by PEPID Newsroom | Jun 4, 2019 | Alerts
Emgality (gacanezumab-gnlm) solution has been FDA approved for treatment of episodic cluster headache in adults, the first of its kind. Emgality was approved in 2018 to prevent migraines in adults, and now has shown to reduce the frequency of cluster headache attaches...
by PEPID Newsroom | Jun 4, 2019 | Alerts
The U.S. FDA approved a new indication for Zerbaxa (Ceftolozane and tazobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABD/VABP) in patients 18 years and older. This approval addresses the threat of...
